Cyclophosphamide and Azathioprine vs Tacrolimus in Antisynthetase Syndrome-related Interstitial Lung Disease — CATR-PAT  

Interstitial Lung Disease Clinical Trial

Official title: Cyclophosphamide and Azathioprine vs Tacrolimus in Antisynthetase Syndrome-related Interstitial Lung Disease : Multicentric Randomized Phase III Trial

Status Recruiting

Clinical Trial Summary

"Antisynthetase syndrome (ASS) is one of the most severe inflammatory myopathy (IM), due to pulmonary involvement (interstitial lung disease, ILD). Until now, the most commonly used immunosuppresive therapy in Europe is Cyclophosphamide followed by different immunosuppressive drugs as maintenance therapy, including Azathioprine (and so called " European Strategy "). In the USA however, the first-line immunosuppressive treatment is Tacrolimus (so called " American Strategy "). None of these two different strategies has ever been studied prospectively, and there is no clear comparison of short and long-term treatment efficacy and tolerance. Thus, there are yet no evidences helping the clinicians in the therapeutic management of patients with ASS-related ILD.

The aim of this study is therefore to compare both strategies as first line treatments or in relapsing patients : CATR.PAT study is a 52 weeks, randomized, comparative, controlled, open-labeled, phase III, therapeutic clinical trial, comparing two treatment strategies."

Clinical Trial Description

"During the study period, according to randomization into two groups (n=38 patients, respectively), patients will receive either:

• Group 1 & 2 : 3 IV pulses of Methylprednisolone (7.5 mg/kg/day followed by tapering doses of oral Prednisone, started at 1 mg/kg/day from D4 to M12

In association with :

• Group 1 : European Standard of care :

6 IV pulses of Cyclophosphamide (1000 mg) followed from M5 to M12 by oral Azathioprine (2 mg/kg/day), with a maximum of 150 mg/d)

• Group 2 : American Strategy Tacrolimus is given orally from M0 to M12 (started at the initial dose of 2x2mg/d). Tacrolimus doses are regularly adapted to its serum concentration to reach 5-15 ng/ml." ;

Related Conditions & MeSH terms

• Antisynthetase Syndrome (ASS)
• Interstitial Lung Disease
• Lung Diseases
• Lung Diseases, Interstitial
• Myositis
• Syndrome

• NCT number: NCT03770663
• Study type: Interventional
• Source: Assistance Publique - Hôpitaux de Paris
• Contact: Olivier BENVENISTE, MD
• Phone: +33 (0)1 42 16 10 88
• Email: olivier.benveniste@aphp.fr
• Status: Recruiting
• Phase: Phase 3
• Start date: February 5, 2021
• Completion date: January 2, 2024